AUTHOR=Gushchina Valeriya , Kupper Nadja , Schwarzkopf Michael , Frisch Gitta , Piatek Karina , Aigner Cornelia , Michel Alexandra , Schueffl Hemma , Iamartino Luca , Elajnaf Taha , Manhardt Teresa , Vlasaty Andrea , Heffeter Petra , Bassetto Marcella , Kállay Enikö , Schepelmann Martin TITLE=The calcium-sensing receptor modulates the prostaglandin E2 pathway in intestinal inflammation JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1151144 DOI=10.3389/fphar.2023.1151144 ISSN=1663-9812 ABSTRACT=

Introduction: The prostaglandin E₂ (PGE₂) pathway is one of the main mediators of intestinal inflammation. As activation of the calcium-sensing receptor (CaSR) induces expression of inflammatory markers in the colon, we assessed the impact of the CaSR on the PGE₂ pathway regulation in colon cancer cells and the colon in vitro and in vivo.

Methods and Results: We treated CaSR-transfected HT29 and Caco-2 colon cancer cell lines with different orthosteric ligands or modulators of the CaSR and measured gene expression and PGE₂ levels. In CaSR-transfected HT29^CaSR-GFP and Caco-2^CaSR-GFP cells, the orthosteric CaSR ligand spermine and the positive allosteric CaSR modulator NPS R-568 both induced an inflammatory state as measured by IL-8 gene expression and significantly increased the expression of the PGE₂ pathway key enzymes cyclooxygenase (COX)-2 and/or prostaglandin E₂ synthase 1 (PGES-1). Inhibition of the CaSR with the calcilytic NPS 2143 abolished the spermine- and NPS R-568-induced pro-inflammatory response. Interestingly, we observed cell-line specific responses as e.g. PGES-1 expression was affected only in HT29^CaSR-GFP but not in Caco-2^CaSR-GFP cells. Other genes involved in the PGE₂ pathway (COX-1, or the PGE₂ receptors) were not responsive to the treatment. None of the studied genes were affected by any CaSR agonist in GFP-only transfected HT29^GFP and Caco-2^GFP cells, indicating that the observed gene-inducing effects of spermine and R-568 were indeed mediated by the CaSR.

In vivo, we had previously determined that treatment with the clinically approved calcimimetic cinacalcet worsened symptoms in a dextran sulfate sodium (DSS)-induced colitis mouse model. In the colons of these mice, cinacalcet significantly induced gene expression of PGES-2 and the EP3 receptor, but not COX-2; while NPS 2143 increased the expression of the PGE₂-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Importantly, neither treatment had any effect on the colons of non-DSS treated mice.

Discussion: Overall, we show that activation of the CaSR induces the PGE₂ pathway, albeit with differing effects in vitro and in vivo. This may be due to the different microenvironment in vivo compared to in vitro, specifically the presence of a CaSR-responsive immune system. Since calcilytics inhibit ligand-mediated CaSR signaling, they may be considered for novel therapies against inflammatory bowel disease.